Pamela B Allen1, Jane N Winter2. 1. Division of Hematology/Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA. pallen5@emory.edu. 2. Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
Abstract
PURPOSE OF REVIEW: Availability of highly effective novel agents has altered the approach to initial therapy in patients with classical Hodgkin lymphoma (cHL). We will review controversies in the following areas: (1) the role of radiation in early unfavorable disease and the optimal treatment strategies for (2) advanced-stage disease and (3) elderly patients. RECENT FINDINGS: Strategies incorporating brentuximab vedotin into frontline treatment of cHL yielded favorable results in non-randomized elderly studies and were compared to ABVD in advanced disease among adults. Meanwhile, four cycles of escalated BEACOPP yielded unprecedented favorable results for the treatment of advanced disease in the German Hodgkin Study Group 18 study. The addition of novel agents to conventional treatment strategies has the potential to improve outcomes in high-risk groups of patients while reducing toxicity. The role of radiation therapy remains in question but may see diminished use with the incorporation of more effective agents in the frontline setting.
PURPOSE OF REVIEW: Availability of highly effective novel agents has altered the approach to initial therapy in patients with classical Hodgkin lymphoma (cHL). We will review controversies in the following areas: (1) the role of radiation in early unfavorable disease and the optimal treatment strategies for (2) advanced-stage disease and (3) elderly patients. RECENT FINDINGS: Strategies incorporating brentuximab vedotin into frontline treatment of cHL yielded favorable results in non-randomized elderly studies and were compared to ABVD in advanced disease among adults. Meanwhile, four cycles of escalated BEACOPP yielded unprecedented favorable results for the treatment of advanced disease in the German Hodgkin Study Group 18 study. The addition of novel agents to conventional treatment strategies has the potential to improve outcomes in high-risk groups of patients while reducing toxicity. The role of radiation therapy remains in question but may see diminished use with the incorporation of more effective agents in the frontline setting.
Authors: V Ballova; J-U Rüffer; H Haverkamp; B Pfistner; H K Müller-Hermelink; E Dühmke; P Worst; M Wilhelmy; R Naumann; M Hentrich; H T Eich; A Josting; M Löffler; V Diehl; A Engert Journal: Ann Oncol Date: 2005-01 Impact factor: 32.976
Authors: Gail L Stark; Katrina M Wood; Fergus Jack; Brian Angus; Stephen J Proctor; Penelope R Taylor Journal: Br J Haematol Date: 2002-11 Impact factor: 6.998
Authors: Ercole Brusamolino; Ambrogia Baio; Ester Orlandi; Luca Arcaini; Francesco Passamonti; Vassiliki Griva; William Casagrande; Cristiana Pascutto; Pietro Franchini; Mario Lazzarino Journal: Clin Cancer Res Date: 2006-11-01 Impact factor: 12.531
Authors: Andreas Engert; Petra Schiller; Andreas Josting; Richard Herrmann; Peter Koch; Markus Sieber; Friederike Boissevain; Maike De Wit; Jorg Mezger; Eckhart Duhmke; Normann Willich; Rolf-Peter Muller; Bernhard F Schmidt; Helmut Renner; Hans Konrad Muller-Hermelink; Beate Pfistner; Jurgen Wolf; Dirk Hasenclever; Markus Loffler; Volker Diehl Journal: J Clin Oncol Date: 2003-08-11 Impact factor: 44.544
Authors: Andreas Engert; Jeremy Franklin; Hans Theodor Eich; Corinne Brillant; Susanne Sehlen; Claudio Cartoni; Richard Herrmann; Michael Pfreundschuh; Markus Sieber; Hans Tesch; Astrid Franke; Peter Koch; Maike de Wit; Ursula Paulus; Dirk Hasenclever; Markus Loeffler; Rolf-Peter Müller; Hans Konrad Müller-Hermelink; Eckhart Dühmke; Volker Diehl Journal: J Clin Oncol Date: 2007-07-02 Impact factor: 44.544